Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference



ROCKVILLE, Md., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at 1:30pm ET in New York City at the New York Palace Hotel.


A live webcast link for the presentation can be accessed via the company website at www.novavax.com under Investor Info/Events.


About Novavax


Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax is involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavax is available on the company's website, novavax.com.


CONTACT: Barclay Phillips

SVP, Chief Financial Officer and Treasurer

Novavax, Inc.

240-268-2000


Information non réglementée


Communiqué intégral et original au format PDF :


http://www.actusnews.com/documents_communiques/ACTUS-0-34217-novavax_eng.pdf

© Copyright Actusnews Wire

Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free



Quelle: Actusnews

Novavax Inc. Stock

€13.98
-7.850%
Heavy losses for Novavax Inc. today as the stock fell by -€1.192 (-7.850%).
Currently there is a rather positive sentiment for Novavax Inc. with 4 Buy predictions and 1 Sell predictions.
As a result the target price of 22 € shows a very positive potential of 57.32% compared to the current price of 13.98 € for Novavax Inc..
Like: 0
Share

Comments